Back to Search Start Over

Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy

Authors :
Gianluca Morroni
Roberto Montalti
Sefora Castelletti
Annamaria Masucci
Francesco Barchiesi
Chiara Valeriani
Andrea Giacometti
Lucia Brescini
Marina Mingoia
Marco Vivarelli
Serena Simoni
Brescini, L.
Morroni, G.
Valeriani, C.
Castelletti, S.
Mingoia, M.
Simoni, S.
Masucci, A.
Montalti, R.
Vivarelli, M.
Giacometti, A.
Barchiesi, F.
Source :
BMC Infectious Diseases, BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019)
Publication Year :
2019

Abstract

Background Bloodstream infections (BSI) due to Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) have become an important problem and they are associated with a high mortality rate. The aim of our study was to evaluate the clinical and epidemiological characteristics of KPC-Kp from BSIs. Methods In this retrospective cohort study, conducted in a tertiary referral center in Italy, 112 patients with KPC-Kp BSIs diagnosed between February 2011 and December 2015 were identified. We evaluated the mortality at 30 days from the first positive blood culture. Survivor and non-survivor subgroups were compared to identify predictors of mortality. Results The overall crude mortality was 35%. APACHE II score ≥ 15, septic shock at BSI onset, immunosuppressive therapy during the 30 days before the BSI onset, and the lack of a combination therapy with at least 2 active drugs emerged as independent predictors of mortality. Excluding patients with inadequate therapy, the mortality decreased to 25% while an APACHE II score ≥ 15 and the presence of septic shock remained independently associated with a negative outcome. Two different pulsotypes were identified: pulsotype A belonged to ST512 and carried KPC-3 and pulsotype B belonged to ST307 and carried KPC-2. Conclusions This study confirmed a high mortality rate of KPC-Kp BSIs. The outcome is heavily influenced by the patient’s clinical conditions. A therapeutic approach including a combination with at least two active drugs in vitro can improve the prognosis, unless patients received an appropriate therapy.

Details

Language :
English
Database :
OpenAIRE
Journal :
BMC Infectious Diseases, BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019)
Accession number :
edsair.doi.dedup.....2279fc9fe96e93a0b3c880f2e9d619a8